The first dose-response study of MDG, published in 2016, evaluated a new, non-aqueous, ready-to-use glucagon formulation under development by Xeris Pharmaceuticals, Inc. Haymond et al assessed three doses of MDG (75, 150 and 300 μg).6 Twelve adults with longstanding T1D were treated on different days with three doses of MDG. Here, GCG is linked to type 1 diabetes mellitus.